Two weeks of continuous anti-HER2/neu antibody plus palbociclib produced significant results: tumor regression, 52.74% average volume reduction, and significant inhibition of tumor cell proliferation, efficacy, and prolonged survival. The gene discussed is ERBB2; the disease is neoplasm.